| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 2.133 | 3.614 | 2.325 | 1.586 | 2.147 | 3.619 |
| Total Income - EUR | - | - | - | - | 2.133 | 3.614 | 2.325 | 1.586 | 2.147 | 3.619 |
| Total Expenses - EUR | - | - | - | - | 627 | 4.007 | 913 | 5.099 | 1.487 | 2.898 |
| Gross Profit/Loss - EUR | - | - | - | - | 1.506 | -393 | 1.411 | -3.513 | 660 | 721 |
| Net Profit/Loss - EUR | - | - | - | - | 1.442 | -492 | 1.343 | -3.561 | 526 | 590 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Oncoovi Con Esculap S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 714 | 682 | 2.163 | 1.629 | 1.292 | 890 |
| Current Assets | - | - | - | - | 2.293 | 1.085 | 3.641 | 3.068 | 4.341 | 5.678 |
| Inventories | - | - | - | - | 55 | 839 | 2.359 | 2.416 | 3.117 | 3.191 |
| Receivables | - | - | - | - | 0 | 0 | 0 | 0 | 92 | 0 |
| Cash | - | - | - | - | 2.238 | 246 | 1.283 | 652 | 1.132 | 2.486 |
| Shareholders Funds | - | - | - | - | 1.484 | 963 | 2.285 | -2.165 | -1.633 | -1.034 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 1.523 | 803 | 3.519 | 6.862 | 7.266 | 7.601 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncoovi Con Esculap S.r.l.